Enterprise Innovation

Translating Research into Next Generation Care Through Collaboration

Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

Read More About Us

Enterprise Innovation Metrics from FY20 to FY24

535
New Tech Disclosures
197
Issued US Patents
129
Licenses and Options
20
NewCo Launches
Two researchers in PPE doing experiment
For Inventors and Innovators
Learn about how to collaborate with our team of top-tier business development professionals to bring your innovations to life.
Two men in dark blue suits shaking hands and two women at the table smiling
For Industry, Investors and Partners
Learn about groundbreaking innovations you can partner to fuel a pipeline or launch a new venture.

  

A Caucasian and an Indian woman holding some booklets and talking
Innovation Ecosystem
Learn more about the infrastructure and different components of Enterprise Innovation.
Four medical students in white coats sitting at a table and listening to a lecture
Programs, Offerings and Support
Explore entrepreneurial programming and education offered by Enterprise Innovation and our ecosystem partners.

  

Technology Portfolio

Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.

We also provide access to a diverse selection of tangible materials developed by Weill Cornell Medicine investigators. See the most updated catalog of our ready-for-licensing tangible materials PDF icon here.

Two doctors and two business reps talking
Collaboration Opportunities
Check out our available research opportunities for potential collaborations.

  

Events

African-American man wearing a dark gray suit and tie
Jun 17,2025
2:00pm to 4:00pm
CTL@WCM Office Hours with Eric Bryant
A group of people dressed in business attire sitting in an auditorium and smiling
Jun 24,2025
5:30pm to 8:00pm
2025 Weill Cornell Medicine Biomedical Innovation Challenge
Colorful image of cells
Jun 26,2025
1:00pm to 2:00pm
From Lab to Launch: Navigating the Path from Academia to
Jul 02,2025
9:00am to 5:00pm
NSF I-Corps Regional Course for Startups Hosted by University of

Testimonials

Lisa Placanica, Ph.D.
Lisa Placanica, Ph.D., Senior Managing Director of the Center for Technology Licensing
There’s obviously fantastic research being done at Weill Cornell Medicine. So we want to work with faculty to identify aspects of their research that could be shaped into a product or a service, work with them to develop it and then to forge the partnership with a commercial entity. We also have to have a finger on the pulse of what industry is looking for: what venture firms are investing in, what pharma is trying to fill their pipeline with. And then we make connections between the two. We have to speak the language between the commercial enterprise and the academic researcher.
Randi Silver, Ph.D.
Randi B. Silver, Ph.D., Associate Dean and Professor of Physiology and Biophysics
Enterprise Innovation has galvanized us to move forward as basic scientists, and to look for translational aspects that could be developed, with an industrial partner, for patient care. As a result, we have been able to get traction in exploring various avenues for commercialization with angel investors, pharma, venture capital and, significantly, our own Tri-Institutional Therapeutics Discovery Institute, none of which would have been possible without support from the Daedalus Fund for Innovation.
Dr. Ronald Crystal
Ronald G. Crystal, M.D., Chair of Genetic Medicine and Professor of Medicine
Allying with the right industrial partner is a vital factor in attracting investors, and Enterprise Innovation’s relationships with and access to biopharma and life science leaders make it possible for aspiring scientist/entrepreneurs to find the right match.
Juan Cubillos-Ruiz, Ph.D.
Juan Cubillos-Ruiz, Ph.D., Associate Professor of Microbiology and Immunology in Obstetrics and Gynecology
With the outstanding support provided by Weill Cornell Medicine’s innovation ecosystem, we identified and developed novel small-molecule inhibitors capable of disabling a detrimental pathway in cancer hosts. We are currently partnering with investors to use our inhibitors as a new strategy for enhancing the effectiveness of chemotherapy and immunotherapy in ovarian cancer and other lethal malignancies.

News

Green-gloved hand holding vial of BCG

New Insights into Bladder Cancer Treatment Could Help Improve Immunotherapies

May 29, 2025

A team of researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) is expanding the understanding of how Bacillus Calmette-Guérin (BCG) works as a treatment of bladder cancer— an understanding that could help improve the effectiveness of immunotherapies more broadly.
Three men wearing dark blue suits and holding award plaques

Expanded Funding Program Strengthens Enterprise Innovation’s Ability to Nurture Promising Early-Stage Research

May 21, 2025

To support the continued diversification of Weill Cornell Medicine’s technology portfolio, Enterprise Innovation has created an overarching gap funding superstructure to advance innovation and commercialization opportunities.